Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Horan

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|October 1, 1992
The heart in hypertensionE D Frohlich, C Apstein, A V Chobanian, et al.
European Journal of Pharmacology|June 15, 1993
Pseudoirreversible binding characteristics of [D-Ala2,Glu4]deltorphin and its Cys4 substituted derivative to delta-opioid receptorsK D Wild, P J Horan, A Misicka, et al.
Iscience|October 5, 2019
Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In VivoWhitney A Bullock, April M Hoggatt, Daniel J Horan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 15, 2019
YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular RemodelingChristopher D Kegelman, Jennifer C Coulombe, Kelsey M Jordan, et al.
Journal of Medicinal Chemistry|May 27, 1994
[L-Ala3]DPDPE: a new enkephalin analog with a unique opioid receptor activity profile. Further evidence of delta-opioid receptor multiplicityR C Haaseth, P J Horan, E J Bilsky, et al.
Bone|September 3, 2023
Loss of Nmp4 enhances bone gain from sclerostin antibody administrationCrystal Korff, Michele Adaway, Emily G Atkinson, et al.
Hypertension (Dallas, Tex. : 1979)|September 1, 1985
NIH report on research challenges in nutrition and hypertensionM J Horan, M P Blaustein, J B Dunbar, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2018
Skeletal cell YAP and TAZ combinatorially promote bone developmentChristopher D Kegelman, Devon E Mason, James H Dawahare, et al.
Science Translational Medicine|November 15, 2013
Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndromeRajendra Kedlaya, Shreya Veera, Daniel J Horan, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Agonist and antagonist profiles of [D-Ala2,Glu4]deltorphin and its [Cys4]- and [Ser4]-substituted derivatives: further evidence of opioid delta receptor multiplicityP J Horan, K D Wild, A Misicka, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|October 1, 1992
The heart in hypertensionE D Frohlich, C Apstein, A V Chobanian, et al.
European Journal of Pharmacology|June 15, 1993
Pseudoirreversible binding characteristics of [D-Ala2,Glu4]deltorphin and its Cys4 substituted derivative to delta-opioid receptorsK D Wild, P J Horan, A Misicka, et al.
Iscience|October 5, 2019
Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In VivoWhitney A Bullock, April M Hoggatt, Daniel J Horan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 15, 2019
YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular RemodelingChristopher D Kegelman, Jennifer C Coulombe, Kelsey M Jordan, et al.
Journal of Medicinal Chemistry|May 27, 1994
[L-Ala3]DPDPE: a new enkephalin analog with a unique opioid receptor activity profile. Further evidence of delta-opioid receptor multiplicityR C Haaseth, P J Horan, E J Bilsky, et al.
Bone|September 3, 2023
Loss of Nmp4 enhances bone gain from sclerostin antibody administrationCrystal Korff, Michele Adaway, Emily G Atkinson, et al.
Hypertension (Dallas, Tex. : 1979)|September 1, 1985
NIH report on research challenges in nutrition and hypertensionM J Horan, M P Blaustein, J B Dunbar, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2018
Skeletal cell YAP and TAZ combinatorially promote bone developmentChristopher D Kegelman, Devon E Mason, James H Dawahare, et al.
Science Translational Medicine|November 15, 2013
Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndromeRajendra Kedlaya, Shreya Veera, Daniel J Horan, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Agonist and antagonist profiles of [D-Ala2,Glu4]deltorphin and its [Cys4]- and [Ser4]-substituted derivatives: further evidence of opioid delta receptor multiplicityP J Horan, K D Wild, A Misicka, et al.
Pageof 21